To accelerate the translation of basic discoveries about HIV into advances in vaccine design and evaluation, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has formed a new Vaccine Discovery Branch within the Vaccine Research Program in the Division of AIDS (DAIDS).
"There is broad scientific consensus that designing a safe and effective vaccine to prevent HIV infection will require enormous advances beyond present-day knowledge," says NIAID Director Anthony S. Fauci, M.D. "The NIAID Vaccine Discovery Branch will help remove fundamental obstacles to achieving this goal by focusing intensively on the development and sharing of new knowledge critical to vaccine development."
The new branch is dedicated to monitoring scientific developments in multiple fields related to HIV vaccine discovery, building more bridges between basic researchers and HIV vaccine designers, identifying gaps in knowledge pertinent to a preventive HIV vaccine and promoting research to fill those gaps.
"Cross-fertilization of HIV/AIDS research with the fields of genetics, structural biology, systems biology and others could open up new perspectives on how to overcome major obstacles to HIV vaccine design," says DAIDS Director Carl W. Dieffenbach, Ph.D. "The Vaccine Discovery Branch will be in an ideal position to spot these opportunities, promote the translation of new knowledge about HIV and foster fruitful research collaborations."
In addition, the new branch will
Monitor vaccine discovery efforts and related basic HIV research within NIH, nationally and internationally
Determine funding priorities for vaccine discovery research
Plan, develop, implement and evaluate extramural grants and contracts to support the conduct of fundamental virology and immunology research as it relates to the discovery of novel AIDS vaccine concepts
Foster the development and supply of necessary research reagents and other resources
The Vaccine Discovery Branch also will have chief oversight of the Center for HIV/AIDS Vaccine Immunology (CHAVI), a consortium of universities and academic medical centers established by NIAID to solve major problems in HIV vaccine development and design. A multidisciplinary group of scientists from across DAIDS will continue to participate in overseeing CHAVI.
Jorge Flores, M.D., deputy director of the Vaccine Research Program, will serve as acting chief of the new branch until a national search results in the selection of a new chief. Dr. Flores has been involved in the conduct and administration of vaccine research at NIH since 1979.
Source: NIH/National Institute of Allergy and Infectious Diseases
Related stories:
Scientists identify genetic link that may neutralize HIV
Scientists from the Gladstone Institute of Virology and Immunology (GIVI) and the National Institutes of Allergy and Infectious Diseases (NIAID) have identified a gene that may influence the production of antibodies that neutralize HIV. This new information will likely spur a new approach for making an HIV vaccine that elicits neutralizing antibodies. Neutralizing antibodies, once produced in the host, can attack and checkmate an infecting virus. The research was reported in the September 5 issue of
Science.
Regulatory B cells exist -- and pack a punch
Researchers at Duke University Medical Center have uncovered definitive evidence that a small but potent subset of immune system B cells is able to regulate inflammation.
NIAID describes research priorities to fight drug-resistant tuberculosis
Tuberculosis (TB) has long been one of the world’s great killers. Now, forms of drug-resistant TB--multidrug (MDR) and extensively drug-resistant (XDR)--are occurring at an ominous and accelerating rate. To help in the fight against drug-resistant TB, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has formulated an MDR and XDR TB research agenda.
Leading HIV researchers to collaborate on vaccine development
Two global research organizations dedicated to designing a vaccine against HIV – the International AIDS Vaccine Initiative (IAVI), and the Center for HIV/AIDS Vaccine Immunology (CHAVI) – have signed an agreement to work together to address major biological questions that have slowed development of a safe, effective and affordable AIDS vaccine.
HIV breakthrough: Researchers identify protein that fights immunodeficiency
A Canada-U.S. research team has solved a major genetic mystery: How a protein in some people’s DNA guards them against killer immune diseases such as HIV. In an advance online edition of
Nature Medicine, the scientists explain how the protein, FOX03a, shields against viral attacks and how the discovery will help in the development of a HIV vaccine.
Scientists devise approach that stops HIV at earliest stage of infection
Their study, which appears this week in the online Early Edition of the Proceedings of the National Academy of Sciences (PNAS), may re-energize attempts to create a preventive/therapeutic vaccine against HIV, say the authors. To date, more than a dozen candidate vaccines, which have attempted to raise immunity against the spiky proteins on the viral envelope, have all failed in clinical testing.
Lack of political will and the subordination of women are major barriers to tackling AIDS
Denial, myths, complacency, lack of political will and the subordination of women are major obstacles in the fight against HIV and AIDS. And with no cure or vaccine in sight, scaling up prevention is of paramount importance, according to Professor Lars Kallings, a leading expert in the global fight against the world’s first modern pandemic.
Experimental HIV vaccine gets a boost from ’70s-era discovery
Although science is known for being a forward-looking field, researchers have found that they can often benefit from a glance over their shoulders. By combining an experimental AIDS vaccine with a long-neglected molecule called poly-IC, Rockefeller University scientists discovered that they were able to significantly improve its effectiveness. Their new, bolstered vaccine not only stimulated the production of HIV-attacking immune cells in mice, but also allowed the rodents to maintain immunity over a significantly longer period of time.